Clinical trial

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-06-25

PhasePHASE3

Study timeline

Study start (actual)2014-06-25Date precision: day

Registry last updated2019-07-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Interventions

CarboplatinDRUG · verified · RxNorm: carboplatin

DocetaxelDRUG · verified · RxNorm: docetaxel

PertuzumabDRUG · verified · RxNorm: pertuzumab

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Trastuzumab EmtansineDRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

TaipeiTaiwan5 SeoulSouth Korea4 MadridSpain4 TorontoOntario, Canada2 BarcelonaSpain2 MontrealQuebec, Canada2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 NashvilleTennessee, United States1 OrlandoFlorida, United States1 CharlestonSouth Carolina, United States1 MoscowRussia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02131064 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.